Renal cell cancer presented with leptomeningeal carcinomatosis effectively treated with sorafenib

Onkologie

Volumn 30, Issue 8-9, 2007, Pages 450-451

  Ranze, Oliver ^a   Hofmann, Erich ^a   Distelrath, Andrea ^a   Hoeffkes, Heinz Gert ^a  

^a KLINIKUM FULDA   (Germany)

Author keywords

Advanced renal cell cancer; Leptomeningeal carcinomatosis; Sorafenib

Indexed keywords

DEXAMETHASONE; SORAFENIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ARTICLE; BRAIN METASTASIS; CASE REPORT; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DRUG EFFICACY; FEMALE; HUMAN; KIDNEY CANCER; LEPTOMENINX CARCINOMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL; REMISSION; TREATMENT RESPONSE; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; MENINGIOMA; METASTASIS; MIDDLE AGED;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; MALE; MENINGEAL NEOPLASMS; MIDDLE AGED; PYRIDINES;

EID: 35348916550     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000105131     Document Type: Article

References (4)

1. American Cancer Society: Cancer Facts and Figures 2006. Atlanta, American Cancer Society, 2006.
2. Escudier B, Szczylik C, Eisen T, Oudard S, Stadler WM, Schwartz B, Shan M, Bukowksi RM, Group FtB-TCT: Randomized phase III trial of the multi-kinase inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma. Eur J Cancer 2005;3:abstr 749.
3. Hilger RA, Scheulen ME, Strumberg D: The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie 2002;25:511-18.
4. Massard C, Zonierek J, Laplanche A, Schwartz B, Szczylik C, Escudier B: Incidence of brain metastasis in advanced renal cell carcinoma among patients randomized in a phase III trial of sorafenib, an oral multi-kinase inhibitor. Ann Oncol 2006;17:abstr 454P.